Paradigm Biopharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PBIGF research report →
Companywww.paradigmbiopharma.com
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
- CEO
- Paul John Rennie
- IPO
- 2019
- HQ
- Melbourne, VIC, AU
Price Chart
Valuation
- Market Cap
- $52.18M
- P/E
- -1.89
- P/S
- 1180.60
- P/B
- 11.38
- EV/EBITDA
- -1.42
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -161.09%
- Op Margin
- -63782.77%
- Net Margin
- -59585.74%
- ROE
- -265.55%
- ROIC
- -492.97%
Growth & Income
- Revenue
- $52.12K · -20.79%
- Net Income
- $-18,770,745 · 68.00%
- EPS
- $-0.06 · 70.15%
- Op Income
- $-22,886,205
- FCF YoY
- 75.75%
Performance & Tape
- 52W High
- $0.35
- 52W Low
- $0.12
- 50D MA
- $0.17
- 200D MA
- $0.21
- Beta
- -0.02
- Avg Volume
- 9.37K
Get TickerSpark's AI analysis on PBIGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PBIGF Coverage
We haven't published any research on PBIGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PBIGF Report →